OncoMatch/Clinical Trials/NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Is NCT06284122 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for follicular lymphoma.
Treatment: Mosunetuzumab · Lenalidomide · Rituximab · Obinutuzumab · Cyclophosphamide · Doxorubicin · Vincristin · Prednisone · Rituximab · Obinutuzumab · Bendamustin — This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive)
CD20+ follicular lymphoma
Disease stage
Required: Stage ALL ANN ARBOR STAGES (Ann Arbor)
Grade: 123a (WHO 2016/2022)
All Ann Arbor stages (including stage I if FLIPI ≥ 2)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: localized radiotherapy
Prior localized radiotherapy for the FL
Cannot have received: anti-cancer drug therapy
Use of any standard or experimental anti-cancer drug therapy within 42 days of the start (Day 1) of study treatment
Lab requirements
Blood counts
ANC ≥ 1 x 10^9/L; platelet count ≥ 75 x 10^9/L (≥ 30 x 10^9/L if bone marrow infiltration or splenomegaly); hemoglobin ≥ 8.0 g/dL unless related to bone marrow infiltration or splenomegaly
Kidney function
creatinine clearance ≥ 40 mL/min (MDRD or Cockcroft-Gault)
Liver function
AST or ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver/pancreatic involvement); serum total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert syndrome; ≤ 3 x ULN if liver/pancreatic involvement)
Cardiac function
LVEF within normal range (> 50% by TTE or > 45% by MUGA)
Adequate hematological function within 28 days prior to signing informed consent... Normal laboratory values: creatinine clearance ≥ 40 mL/min... AST or ALT ≤ 2.5 x ULN... serum total bilirubin ≤ 1.5 x ULN... LVEF within normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06284122 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage ALL ANN ARBOR STAGES is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages